Sanofi India Limited has notified stock exchanges about the availability of video recording from its recent investors and analysts call. The pharmaceutical company communicated this development to BSE Limited and National Stock Exchange of India Limited on February 27, 2026.

Investor Call Details

The company conducted its investors/analysts call on February 26, 2026, at 4:00 pm to discuss the financial performance for Q4FY25 and FY25. The call focused on financial results for the quarter and year ended December 31, 2025.

Regulatory Compliance

The notification was made pursuant to Regulation 30 read with Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulatory framework mandates listed companies to disclose material information and events to ensure transparency for investors and stakeholders.

The communication was signed by Haresh Vala, Company Secretary & Compliance Officer (Membership No: A18246), and digitally authenticated on February 27, 2026, at 15:28:05 +05'30'.

Accessibility

Sanofi India has made the video recording accessible to investors and analysts through its official website. The recording is available in the Analyst/Investor Meet section, allowing stakeholders to review the detailed discussions about the company's financial performance for the concluded quarter and fiscal year.

Sanofi India Limited has received a significant tax demand order from the Commercial Tax Officer in Tiruvalur, Tamil Nadu, totaling ₹2.37 crore for the financial year 2021-22. The pharmaceutical company disclosed this development in compliance with SEBI listing regulations on 20th February 2026.

Tax Demand Breakdown

The order issued by the Commercial Tax Officer presents a comprehensive demand structure across multiple components:

Nature of Dispute

The tax controversy stems from Input Tax Credit (ITC) claims related to FY 2020-21 that were subsequently claimed in FY 2021-22. The Commercial Tax Officer dismissed the company's submissions and reconciliations regarding the eligibility of these ITC claims, leading to the substantial tax demand.

Timeline and Receipt Details

The order was originally dated 30th December 2025, but Sanofi India received the communication on 19th February 2026. This timeline indicates a significant delay between the order issuance and the company's receipt of the official communication.

Company's Response Strategy

Sanofi India has indicated its intention to challenge the order through appropriate legal channels. The company stated it would make an appeal before the appellate authorities, suggesting confidence in its position regarding the ITC claims that were disputed by the tax officer.

Regulatory Compliance

The disclosure was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, demonstrating the company's commitment to transparency with stakeholders regarding material developments that could impact its operations.